Sandoz and EirGenix to market Herceptin biosimilar

01-05-2019

Sandoz and EirGenix to market Herceptin biosimilar

hafakot / Shutterstock.com

A division of Novartis has entered into an agreement with Taiwan-based EirGenix to market a medicine which treats some cancer tumours.


Novartis, Sandoz, EirGenix, trastuzumab, breast cancer, stomach cancer, biosimilar

LSIPR